Cholesterol and Diabetes Drugs May Lessen Risk of Age Related Macular Degeneration

Summary: A new study reports regular usage of medications to control type 2 diabetes and lower cholesterol may decrease the risk of developing age-related macular degeneration.

Source: BMJ

Regular use of drugs to lower cholesterol and control type 2 diabetes may lessen the risk of the degenerative eye disease associated with aging, known as AMD, finds a pooled data analysis of the available evidence, published online in the British Journal of Ophthalmology.

These common drugs are linked to lower prevalence of AMD (age related macular degeneration) in European populations, the results show.

AMD is the leading cause of severe visual impairment among older people in high-income countries. In Europe alone, 67 million people currently have the condition, with new cases projected to soar over the next few decades as populations age.

AMD affects central vision and the ability to see fine detail. Various genetic and environmental factors associated with aging are thought to trigger AMD, but it’s still not clear how best to prevent it or slow its progression.

Previously published research suggests that drugs to lower cholesterol, control diabetes, and dampen down inflammation may help to lessen the risk of developing AMD, but these findings were partly contradictory and based on small numbers of participants.

In a bid to get round these issues, the researchers pooled the results of 14 population-based and hospital-based studies, involving 38,694 people from France, Germany, Greece, Ireland, Italy, Norway, Portugal, Russia and the UK.

The studies were part of the European Eye Epidemiology (E3) consortium, a collaborative pan European network, the principal aim of which is to develop and analyze large pooled datasets to further the understanding of eye disease and sight loss.

Participants were all over the age of 50 and taking at least one of the following types of drug to: lower cholesterol, including statins; control diabetes, including insulin; to dampen down inflammation, excluding steroids; and Levodopa, used to treat movement disorders caused by neurodegenerative disease.

The prevalence of AMD ranged from 12% to 64.5% across the included studies—9332 cases in total—while the prevalence of advanced (late) AMD ranged from 0.5% to 35.5%—951 cases in total.

This shows a man's eye
These common drugs are linked to lower prevalence of AMD (age related macular degeneration) in European populations, the results show. Image is in the public domain

The pooled data analysis showed that drugs to lower cholesterol or control diabetes were associated with, respectively, 15% and 22% lower prevalence of any type of AMD, after accounting for potentially influential factors.

No such associations were found for any of the other types of drug or for advanced AMD, in particular, although there were only a relatively small number of such cases, note the researchers.

Theirs is the first large pooled data analysis of its kind to use individual level data from various population-based and hospital-based studies, highlight the researchers. 

“Yet, further longitudinal data are needed to confirm our findings, which are inherently limited by using cross-sectional data only and cannot infer causality,” they caution.

But the findings point to a likely key role for metabolic processes in the development of AMD, which may offer potential new avenues for treatment and have implications for public health messaging, they suggest.

“Our study suggests that regular intake of [lipid lowering] and antidiabetic drugs is associated with reduced prevalence of AMD in the general population. Given a potential interference of these drugs with pathophysiological pathways relevant in AMD, this may contribute to a better understanding of AMD etiology,” they conclude.

About this age-related macular degeneration research news

Author: BMJ Media Relations
Source: BMJ
Contact: BMJ Media Relations – BMJ
Image: The image is in the public domain

Original Research: Open access.
Association of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration: a meta-analysis in Europeans” by Matthias M Mauschitz et al. British Journal of Opthalmology


Association of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration: a meta-analysis in Europeans


To investigate the association of commonly used systemic medications with prevalent age-related macular degeneration (AMD) in the general population.


We included 38 694 adults from 14 population-based and hospital-based studies from the European Eye Epidemiology consortium. We examined associations between the use of systemic medications and any prevalent AMD as well as any late AMD using multivariable logistic regression modelling per study and pooled results using random effects meta-analysis.


Between studies, mean age ranged from 61.5±7.1 to 82.6±3.8 years and prevalence ranged from 12.1% to 64.5% and from 0.5% to 35.5% for any and late AMD, respectively. In the meta-analysis of fully adjusted multivariable models, lipid-lowering drugs (LLD) and antidiabetic drugs were associated with lower prevalent any AMD (OR 0.85, 95% CI=0.79 to 0.91 and OR 0.78, 95% CI=0.66 to 0.91). We found no association with late AMD or with any other medication.


Our study indicates a potential beneficial effect of LLD and antidiabetic drug use on prevalence of AMD across multiple European cohorts. Our findings support the importance of metabolic processes in the multifactorial aetiology of AMD.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.